Investors across several industries and affiliations will be keeping a close eye on Bio-Rad Laboratories as it continues to make strides within both its Life Sciences and Clinical Diagnostics segments.

With this positive showing and the recent increase in holdings by Dimensional Fund Advisors LP, equity research analysts have high hopes for Bio-Rad Laboratories’ current fiscal year. The quarter ended with revenue of $676.80 million against an earlier estimate of $689.28 million – a decrease of 3.3% from the same quarter last year. The firm reported an EPS of $3.34 for the quarter – a figure that exceeded analysts’ expectations by $0.10. With this growth, Dimensional Fund Advisors LP now has a total of 186,134 shares in the company, valued at $78,271,000.īio-Rad Laboratories (NYSE:BIO), which specializes in producing specialty chemicals for use in biochemical and pharmaceutical research applications, recently released its earnings results on Thursday, May 4th. This announcement was made following the company’s most recent disclosure with the Securities and Exchange Commission (SEC). Dimensional Fund Advisors LP, a leading institutional investor based in Texas, recently announced that its holdings in the medical research firm Bio-Rad Laboratories, Inc.

Stocks rad